Jazz Pharmaceuticals (JAZZ) and Osiris Therapeutics (OSIR) Head to Head Review

Jazz Pharmaceuticals (NASDAQ: JAZZ) and Osiris Therapeutics (OTCMKTS:OSIR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings and institutional ownership.

Profitability

This table compares Jazz Pharmaceuticals and Osiris Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Jazz Pharmaceuticals 23.58% 22.92% 10.07%
Osiris Therapeutics N/A N/A N/A

Earnings and Valuation

This table compares Jazz Pharmaceuticals and Osiris Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Jazz Pharmaceuticals $1.49 billion 6.05 $396.83 million $6.07 24.74
Osiris Therapeutics N/A N/A N/A N/A N/A

Jazz Pharmaceuticals has higher revenue and earnings than Osiris Therapeutics.

Analyst Recommendations

This is a summary of recent ratings for Jazz Pharmaceuticals and Osiris Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jazz Pharmaceuticals 0 5 17 0 2.77
Osiris Therapeutics 0 0 0 0 N/A

Jazz Pharmaceuticals presently has a consensus price target of $183.41, indicating a potential upside of 22.12%. Given Jazz Pharmaceuticals’ higher possible upside, research analysts plainly believe Jazz Pharmaceuticals is more favorable than Osiris Therapeutics.

Volatility and Risk

Jazz Pharmaceuticals has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Osiris Therapeutics has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

Institutional & Insider Ownership

90.7% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 0.3% of Osiris Therapeutics shares are held by institutional investors. 4.3% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 44.6% of Osiris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Jazz Pharmaceuticals beats Osiris Therapeutics on 8 of the 9 factors compared between the two stocks.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).

About Osiris Therapeutics

Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply